Efficacy and Safety on SOM3355 in Huntington's Disease Chorea

Summary

Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington's Disease with choreic movements.

Timeline

Start

2022-08-02

Primary completion

2024-06-25

Completion

2024-07-15

Outcome

Met primary endpoint

registry analysis (other test); Placebo vs SOM3355 600 mg/Day; p = 0.045; Mean Difference (Final Values) -1.27 (95% CI -2.51 to -0.03); Mixed Models Analysis NCT05475483 ↗

Drugs

Indications